Biotechnology

Chemotherapy may affect muscle cells at lower doses than previously thought

12/01/2021

The cancer therapy may also affect the protein building process, not just cause muscles to degrade Date:November 18, 2021 Source:Penn State Summary:Previous research has found that chemotherapy can trigger muscle loss in people living with cancer, but a new study out of found it may also affect the way the body builds new muscle —…

Read More

A stealthy way to combat tumors

12/01/2021

Biologists show that helper immune cells disguised as cancer cells can help rejuvenate T cells that attack tumors Date:November 19, 2021 Source:Massachusetts Institute of Technology Summary:Researchers uncovered a new way to indirectly activate T cells that can target tumors, by recruiting a population of helper immune cells called dendritic cells. Excerpt from the Press Release:…

Read More

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

11/29/2021

Excerpt from the Press Release: KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this…

Read More

Second Genome Presents Preclinical Data at Crohn’s & Colitis Foundation’s® IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455

11/25/2021

SG-5-00455 delivered directly to the gut via engineered L. lactis system restores barrier function and improves mucosal healing in an ulcerative colitis model Company also participates as new Crohn’s & Colitis Foundation Corporate Circle member to support Foundation’s IBD treatment, awareness and patient engagement initiatives Excerpt from the Press Release: BRISBANE, Calif. – November 18,…

Read More

UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event

11/19/2021

New, Single-arm Phase 3 Study Expected to Initiate in Early 2022 Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, is announcing at its virtual Spotlight Event being held today that, following recent discussions with the…

Read More

Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

11/17/2021

Initial Safety and Efficacy Data for NKTR-255, a Novel IL-15 Agonist, in Combination with Cetuximab in Solid Tumors Presented in Late-Breaking Abstract Session SAN FRANCISCO, Nov. 12, 2021 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. Excerpt from the Press Release: Initial clinical…

Read More

Alto Neuroscience Announces Publication in Nature Neuroscience Highlighting Superiority of Data-Driven Framework for Mapping Human Neurobiology Domains

11/16/2021

–Publication highlights first ever, most comprehensive data-driven neurobiological mapping of the mind– –Findings, published in Nature Neuroscience, validate Alto’s rigorous high-science approach and may be translated to future drug discovery and development– –Intellectual property has been exclusively licensed to Alto by Stanford– Excerpt from the Press Release: LOS ALTOS, Calif.–(BUSINESS WIRE)–Alto Neuroscience today announced the publication of the…

Read More

Elicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Immunotherapy of Cancer Annual Meeting

11/15/2021

Excerpt from the Press Release: Data showed Amphiphile (AMP) boosting significantly enhanced TCR-T cell anti-tumor efficacy and led to durable responses against solid tumors in an established, syngeneic tumor model AMP boosting of CD19-specific CAR-T cells led to enhanced CAR-T activation and effector function suggesting the platform can potentially be utilized to improve clinical CD19…

Read More

MAGENTA THERAPEUTICS ANNOUNCES DATA PRESENTATIONS RELATED TO ITS MOBILIZATION AND CONDITIONING PROGRAMS AT THE 2021 AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

11/11/2021

— Positive topline clinical data from MGTA-145 investigator-initiated Phase 2 clinical trial in multiple myeloma — — Successful conditioning with monotherapy CD117 antibody drug conjugate in a primate model of transplant for gene therapy of sickle cell disease — — Successful conditioning with CD117 antibody drug conjugate in combination with lymphodepleting antibodies leading to effective…

Read More

Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies

11/05/2021

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the first patient has been dosed in KZR-261-101, a Phase 1 clinical trial evaluating KZR-261, a novel, broad-spectrum, anti-tumor agent that acts through direct…

Read More